Keywords
Abstract
Prediabetes negatively influences heart failure progression even before the onset of overt diabetes. This study evaluated the clinical and functional impact of SGLT2 inhibitors in patients with chronic heart failure (CHF) and prediabetes compared with CHF patients with normal glucose metabolism. Forty patients were examined: 20 with CHF and prediabetes (main group) and 20 with CHF without carbohydrate metabolism disorders (control). Over 12 weeks, patients in the main group received SGLT2 inhibitors in addition to standard therapy. The treatment led to improved metabolic indicators, better exercise tolerance, and more favorable echocardiographic changes compared with controls. The findings support the potential value of SGLT2 inhibitors in CHF patients at the prediabetic stage.
References
Luo Y., Zhang X., Li J., et al. Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis // Cardiovascular Diabetology. — 2024. — Vol. 23. — P. 2–14.
Narasimhan S., Martinez C., Patel H., et al. Sodium-glucose cotransporter-2 inhibitors reduce the risk of incident type 2 diabetes in people with heart failure without diabetes: real-world cohort data // Diabetes, Obesity and Metabolism. — 2024. — doi:10.1111/dom.15396.
Ahmed F., Raza S., Collins L., et al. SGLT2 inhibitors in non-diabetic heart failure: systematic review of randomized controlled trials and real-world evidence // Journal of Cardiac Failure. — 2023. — doi:10.1016/j.cardfail.2023.11.005.